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Abstract
Objectives: The expression of survivin, an inhibitor of apoptosis, in tumor cells is associated with poor clinical
outcome for various cancers. We conducted this study to determine survivin expression in patients with adenoid
cystic carcinoma (ACC) of the head and neck and to identify its clinical significance as a prognostic factor.
Materials and methods: We performed immunohistochemical staining for survivin, p53, bcl-2 protein, and Ki-67 in
formalin fixed, paraffin-embedded blocks from 37 cases of head and neck ACC. We also reviewed the patients’
clinical records to determine the association of staining with clinical course.
Results: Of the 37 cases of head and neck ACC, 31 (83.8%) were positive for cytoplasmic survivin expression, and
23 (62.2%) were positive for nuclear survivin expression. There was a significant association between nuclear
survivin expression and bcl-2 (P = 0.031). A larger tumor was more commonly a survivin-positive tumor
(cytoplasmic survivin, P = 0.043; nuclear survivin, P = 0.057). Median overall survival (OS) was significantly longer in
patients not expressing nuclear survivin (P = 0.035). A multivariate analysis revealed that nuclear survivin expression
significantly impacted OS (hazard ratio 8.567, P = 0.018) in addition to lymph node involvement (hazard ratio 7.704,
P = 0.016).
Conclusions: The immunohistochemical expression of nuclear survivin has a prognostic impact in patients with
head and neck ACC. These results suggest that nuclear survivin expression may be a useful biomarker for
predicting prognosis in patients with head and neck ACC who were treated with surgical resection.
Background
Adenoid cystic carcinoma (ACC) is an uncommon epithe-
lial tumor that constitutes about 10% of all head and neck
tumors. Unlike squamous cell head and neck cancer
(HNSCC), ACC has been described as a tumor with indo-
lent but persistent and recurrent growth and late onset of
metastases, which eventually leads to death [1]. Several
studies have identified clinicopathological factors in ACC
with an unfavorable effect on survival, including old age,
tumor location, advanced stage, solid histological subtype,
high grade, major nerve involvement, the presence of peri-
neural invasion, a positive surgical margin, and lymph
node metastasis [2,3]. The primary treatment for ACC is
surgery, which is usually followed by post-operative radio-
therapy. Although systemic chemotherapy has been used
for recurrent or metastatic ACC, there is substantial doubt
about its effectiveness and whether systemic therapy
impacts on the disease course.
Additional predictors of ACC biologic activity might
prove helpful for the clinical management of patients and
could be a target of molecular therapy. Biologic prognos-
tic factors including KIT, epidermal growth factor recep-
tor, human epidermal growth receptor-2, estrogen and
progesterone receptors, proliferating cell nuclear antigen,
Ki-67, and the p53, bcl-2 and SOX-4 genes, have been
extensively investigated and are candidates for targeted
therapy [4]. However, the results from studies on the
effectiveness of several molecular targeted therapies for
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studies are needed for current molecular targeted therapy
and further research into novel molecular targets is
urgently necessary.
Survivin is one of the most cancer-specific proteins
identified to date. It belongs to the apoptosis inhibitor
gene family, in which the proteins are characterized by a
domain of about 70 amino acids, termed baculovirus
inhibitor of apoptosis proteins (IAPs) repeat (BIR) [5].
Unlike other IAPs, survivin is small and has only a single
N-terminal BIR domain, a long C-terminal alpha-helix
coiled region, and forms a stable dimmer in solution. It
inhibits apoptosis differently than bcl-2 either by directly
or indirectly interfering with caspase-3 and caspase-7
function via its BIR domain. Survivin also counteracts
cell death by interfering with caspase-9 processing, the
upstream inhibitor in the intrinsic pathway of apoptosis
[6]. Furthermore, survivin enhances cell proliferation and
promotes angiogenesis. Survivin is expressed during
embryonic and fetal development but is undetectable in
terminally differentiated normal adult tissue. However, it
is re-expressed in transformed cell lines and several
human cancer cells at a frequency of 34-100% [7]. High
survivin expression is significantly associated with poor
clinical outcomes in various cancers [8-13], including
HNSCC [12]. Thus, because of its upregulation in malig-
nancy, it has become of great interest as both a tumor
diagnostic and prognostic marker, as well as a new sub-
stantial biologic target for future anti-cancer therapies
[14]. However, survivin expression in patients with head
and neck ACC has not been studied. Moreover, the
impact of survival on clinicopathological characteristics
and prognosis is unknown.
We investigated the degree of proliferative activity
using Ki-67 and the expression of other apoptosis related
proteins, bcl-2 and p53. Ki-67 is a nuclear antigen
expressed mainly in the S and M phases of the cell cycle,
and it has been used for estimating the growth fraction in
many studies investigating various tumor types and also
in a variety of malignant salivary gland tumors [15]. Bcl-2
proteins play a key role in preventing programmed cell
death by favoring prolonged survival in normal and neo-
plastic cells [16]. The bcl-2 oncoprotein is also proving
useful as an investigative tool in oral pathology [17].
Similarly, the p53 protein stimulates the transcription of
several genes that mediate cell cycle arrest, and this pro-
tein initiates apoptosis in response to DNA damage.
While the wild-type p53 protein makes tumor differentia-
tion possible, the mutant p53 protein blocks it [18].
Thus, in the present study, we examined survivin
expression in surgical specimens from patients with
head and neck ACC using tissue microarray and immu-
nohistochemical methods. We also investigated survivin
expression in patients with head and neck ACC and its
association with other biologic markers and clinical
outcomes.
Methods
Patients and specimens
This study was approved by the Uijeongbu St. Mary’s
hospital institutional review board. All of the tissues
investigated were obtained from 42 consecutive patients
with head and neck ACC who underwent a primary
resection between April 1997 and March 2003 at Seoul
St. Mary’s Hospital, the Catholic University of Korea.
Paraffin blocks with the tumor samples were available
from 37 patients. The demographic features of these
patients are summarized in Tables 1 and 2. The median
follow-up time was 83.5 months (range, 8.2-213.9), and
the median age of the patients was 53 years (range, 28-75
years). According to the American Joint Committee on
Cancer staging criteria, 19 patients (51.4%) had stage I
and II disease, and 18 patients (48.6%) had stage III and
IV disease. Four patients (10.8%) had positive lymph
nodes and 33 (89.2%) had negative lymph nodes. At the
end of the follow-up period, 18 patients (48.6%) had died,
and the median overall survival time was 164.4 months
(95% confidence intervals (CI), 50.830-277.970).
Construction of the tissue microarray
All archival tissue samples were routinely fixed in forma-
lin and embedded in paraffin wax. Representative tissue
areas were marked on standard hematoxylin and eosin
stained sections that were cut from the blocks; these
Table 1 Baseline clinical and medical characteristics of
patients with head and neck adenoid cystic carcinoma
Characteristics Total
No. of patients %
No. of patients 37
Age (years), median (range) 53.0 (28 - 75)
Gender
Male 14 37.8
Female 23 62.2
Primary site
Major salivary gland* 14 37.8
Minor salivary gland
† 23 62.2
Stage
I 7 18.9
II 12 32.4
III 11 29.7
IV 7 18.9
Lymph node involvement
Positive 4 10.8
Negative 33 89.2
* submandibular gland, parotid gland, sublingual gland.
† maxillary sinus, nasal cavity, base of tongue, floor of the mouth, external
acoustic canal.
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fin block using a 2.0-mm punch, and the cores were
inserted into a recipient paraffin block. To decrease any
error introduced by sampling and to minimize the impact
of tissue loss during processing, duplicate tissue cores per
specimen were arrayed on a second recipient paraffin
block. Sections (5 μm) were cut from the completed
array block and transferred to silanized glass slides.
Immunohistochemistry and analysis
Immunohistochemical staining was performed on 5 μm
sections of the tissue microarray blocks using a Lab Vision
Autostainer LV-1 (LabVision/Neomarkers, Fremont, CA,
USA), according to the manufacturer’s protocol. Paraffin
sections were mounted on superfrost glass slides, deparaf-
finized, and rehydrated in a graded ethanol series. The
antigen was retrieved with 0.01 M citrate buffer (pH 6.0)
by heating the sample in a microwave vacuum histopro-
cessor (RHS-1, Milestone, Bergamo, Italy) at a controlled
final temperature of 121°C for 15 min. Endogenous perox-
idase activity was blocked by incubating the slides in 3%
hydrogen peroxide in methanol for 10 min. The primary
antibodies were diluted in Dako Antibody Diluent (Dako,
Carpentaria, CA, USA) with background-reducing compo-
nents and were used at the following dilutions: survivin
(1:1000, polyclonal, Novus, Littleton, CO, USA), p53
(1:100, clone DO-7, monoclonal, Dako), bcl-2 (1:100,
clone 124, Dako), and Ki-67 (1:50, clone MIB-1, Dako).
The primary antibodies were incubated at room tempera-
ture for 30 min and detected using the Envision Plus Sys-
tem (Dako). The immunoreaction was developed with
diaminobenzidine (Dako) for 5 min and counterstained
with hematoxylin. Results were interpreted by one pathol-
ogist (C.K.J.) who was blinded to the specific diagnosis and
prognosis for each case. For survivin staining, staining
intensities were scored as no staining (0), weak staining
(1+), moderate staining (2+), or strong staining (3+). The
percentage of staining area was classified as 0, 0%; 1, 1-
10%; 2, 11-50%; 3, 51-100%. The intensity and percentage
scores were multiplied to give a composite score of 1-9 for
each specimen. Composite scores of 1-3 were defined as
having low surviving protein expression, and scores of 4-9
were considered to be high expression of survivin. For
bcl-2, p53, and Ki-67 staining, tumors were considered to
be positive expression if ≥10% of tumor cells were
immunostained.
Statistical Methods
Statistical calculations were performed using the SPSS
software package (version 13.0; SPSS, Chicago, IL, USA).
Overall survival was measured from the date of diagno-
sis to the date of death or the last follow-up visit. Survi-
val was derived by the Kaplan-Meier method, and the
statistical differences in the cumulative survival curves
were evaluated using the log-rank test. Multivariate sur-
vival analysis was performed using the Cox proportional
hazard model. All variables with a P-value less than 0.2
in the univariate analysis were selected for the multivari-
ate analysis. The immunohistochemical profiles were
compared to the clinicopathological parameters using
t h ec h i - s q u a r ea n dF i s h e r ’s exact tests. Survival rates
and odds ratios are presented with their 95% confidence
interval (CI). Statistical tests were two-sided at the 5%
level of significance.
Results
Expression of survivin, bcl-2, p53, and Ki-67
Cytoplasmic staining for survivin was observed in 31 of
37 cases (83.8%; Figure 1A), whereas nuclear staining
for survivin was observed in 23 cases (62.2%). Bcl-2 was
strongly expressed mainly in the cytoplasm and mem-
branes of cancer cells, with 51.4% higher scores (19 of
37; Figure 1B). p53 expression was detected in the can-
cer cell nuclei in 9 of 37 cases (24.3%). Four cases
(10.8%) were positive for Ki-67 immunohistochemical
staining. The associations between cytoplasmic/nuclear
survivin and bcl-2, p53, or Ki-67 expression are shown
in Table 3. Nuclear survivin expression was significantly
associated with bcl-2 expression (P = 0.031). There was
a tendency for an association between cytoplasmic survi-
vin and bcl-2 expression, but the difference was not sig-
nificant (P = 0.078).
Table 2 Baseline pathological characteristics of patients
with head and neck adenoid cystic carcinoma
Characteristics Total
No. of patients %
Tumor size (cm) (n = 32)
≤3 cm 14 43.8
>3 cm 18 56.2
Histological growth pattern
Tubular 7 18.9
Cribriform 23 62.2
Solid 7 18.9
Histological grade
Well 6 16.2
Moderately 21 56.8
Poorly 10 27.0
Perineural invasion (n = 34)
Positive 26 76.5
Negative 8 23.5
Perivascular invasion (n = 35)
Positive 4 11.4
Negative 31 88.6
Lymphatic invasion (n = 33)
Positive 11 29.7
Negative 22 66.7
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clinicopathological characteristics
High survivin expression was found more frequently in
tumors greater than 3 cm in diameter (cytoplasmic sur-
vivin, P = 0.043; nuclear survivin, P = 0.057; Table 3)
than in those smaller than 3 cm in diameter. However,
survivin expression was not associated with histological
growth pattern or histological grade. Low bcl-2
expression was marginally associated with perineural
invasion (P = 0.080). There were no significant interac-
tions between bcl-2 expression and any other clinico-
pathological factors (data not shown).
Clinical outcome and survivin expression
Table 4 shows the association of patients’ characteristics
and clinicopathological features with overall survival in
Figure 1 Immunohistochemical staining for survivin, bcl-2, p53, and Ki-67 in adenoid cystic carcinomas. (A) Most tumor cells showed
diffuse nuclear and cytoplasmic staining for survivin (staining score, 3). (B) Bcl-2 was expressed diffusely in the cytoplasm of tumor cells. The
tumor cells showed positive nuclear staining for p53 (C) and Ki-67 (D). Original magnifications ×400, A-D.
Table 3 Relationship among clinicopathological factors and marker expression patterns
C-survivin* N-survivin
†
Low, n(%) High, n(%) P-value Low, n(%) High, n(%) P-value
Histological growth pattern
Tubular, cribriform 6(100) 24(77.4) 0.255 12 (85.7) 18(78.3) 0.459
Solid 0(0) 7(22.6) 2(14.3) 5(21.7)
Grade
Well, moderately 5(83.3) 22(71.0) 0.475 12 (85.7) 15(65.2) 0.164
Poorly 1(16.7) 9(29.0) 2(14.3) 8(34.8)
Stage
I, II 4(66.7) 15(48.4) 0.357 10(71.4) 9(39.1) 0.357
III, IV 2(33.3) 16(51.6) 2(28.6) 14(51.6)
Tumor size
≤ 3 cm 5(83.3) 9(34.6) 0.043
‡ 8(61.5) 11(42.1) 0.057
> 3 cm 1(16.7) 17(65.4) 5(38.5) 8(57.9)
Lymph node involvement
Negative 6(100) 27(87.1) 0.476 6(46.2) 11(87) 0.821
Positive 0(0) 4(10.8) 7(53.8) 3(13)
Bcl-2
Negative 5(83.3) 13(41.9) 0.078 10(71.4) 8(34.8) 0.031
‡
Positive 1(16.7) 18(58.1) 4(28.6) 15(65.2)
Ki-67
Negative 6(100) 27(87.1) 0.476 13(92.9) 20(87) 0.509
Positive 0(0) 4(12.9) 1(7.1) 3(13)
P53
Negative 5(83.3) 23(74.2) 0.543 12(85.7) 16(69.6) 0.267
Positive 1(16.7) 8(25.8) 2(14.3) 7(30.4)
* cytoplasmic survivin.
† nuclear survivin.
‡ statistically significant (P < 0.05).
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median overall survival time was 164.4 months (95% CI,
50.8-278.0) for all patients, with a median overall survi-
val of 120.8 months (95% CI, 28.6-213.0) months for
those with high nuclear survivin expression, and a med-
ian overall survival of 192.5 months (95% CI, 157.8-
227.2) for those with low nuclear survivin expression.
The 71.7-month difference in the overall survival
between the above two groups was statistically signifi-
cant (P = 0.035), whereas the median overall survival
was 120.8 months (95% CI, 39.6-202.0) for patients with
high cytoplasmic survivin expression and was not
reached for those with low expression (median duration,
176.8 months; 95% CI, 123.8-239.8). However, the survi-
val difference was statistically significant (P =0 . 1 6 0 ) .
The expression of any other markers was not signifi-
cantly correlated with overall survival. In addition, clini-
cal parameters including TNM stage, lymph node
involvement, and tumors greater than 3 cm in diameter
were significantly correlated with overall survival (P =
0.001, P = 0.014, and P = 0.036, respectively). The final
multivariate analysis is shown in Table 5 and Figure 2.
The significant predictors were lymph node involvement
and high nuclear survivin expression (P = 0.016 and P =
0.018). However, high cytoplasmic survivin expression
did not achieve a statistically significant level (P =
0.734). Other clinicopathological factors were not statis-
tically associated with overall survival.
Discussion
We examined survivin expression in patients who
underwent resection for head and neck ACC. The
nuclear expression of survivin, which was more fre-
quently observed in larger tumors, was significantly
correlated with unfavorable clinical outcome. To the
best of our knowledge, this study is the first to demon-
strate a significant correlation between survivin expres-
sion and clinical prognosis in patients with resected
ACC of the head and neck. These data suggest that
nuclear survivin expression aggressively identifies cases
of head and neck ACC and, therefore, could influence
the decision for therapy at the time of diagnosis.
Several studies have identified clinicopathological fac-
tors with an unfavorable effect on survival in ACC,
including old age, tumor location, advanced stage, solid
histological subtype, high grade, major nerve involve-
ment, the presence of perineural invasion, and the pre-
sence of a positive surgical margin [2]. In our previous
report, only lymph node involvement was predictive of
overall survival [3]. However, using conventional clino-
pathological criteria, it is difficult to develop an accurate
prognosis and treatment response for advanced head
and neck ACC. When we analyzed the survival biomar-
kers in this study, a stepwise Cox analysis showed that
nuclear survivin was significantly associated with survi-
val. When we analyzed the survival biomarkers in this
study, a stepwise Cox analysis showed that nuclear sur-
vivin was significantly associated with survival.
Table 4 Clinicopathological variables affecting overall
survival (univariate analysis)
Variable P-value (chi-square)
Stage (I, II/III, IV) 0.001*
Lymph node metastasis 0.014*
Tumor size (≤ 3 cm/> 3 cm) 0.036*
Growth pattern (tubular, cribriform/solid) 0.806
Tumor grade (well, moderately/poorly) 0.235
Perineural invasion 0.377
Perivascular invasion 0.926
Lymphatic invasion 0.569
C-survivin
† (high/low) 0.160
N-survivin
‡ (high/low) 0.035*
Bcl-2 (positive/negative) 0.986
Ki-67 (positive/negative) 0.872
p53 (positive/negative) 0.957
* statistically significant (P < 0.05).
† cytoplasmic survivin.
‡ nuclear survivin.
Table 5 Multivariate analysis of the clinicopathological
characteristics and four biological factors by overall
survival rate
Characteristics Hazard ratio 95% CI p-value
N-survivin* 8.567 1.445-50.783 0.018
Lymph node involvement 7.704 1.468-40.434 0.016
CI, confidence interval.
*nuclear survivin.
Figure 2 Kaplan-Meier survival estimate for overall survival of
patients with adenoid cystic carcinoma according to survivin
expression.
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various cancers. Patients with survivin-positive tumors
have a decreased apoptotic index and worse survival
rates than those with survivin-negative tumors. In addi-
tion, survivin expression has been correlated with resis-
tance against chemotherapy- and radiotherapy-induced
apoptosis and abbreviated patient survival [14]. Previous
studies have correlated survivin with an unfavorable
clinical outcome in a variety of cancers, including color-
ectal cancer [8], breast cancer [9], lung cancer [10], eso-
phageal cancer [11], brain tumor [13], soft tissue
sarcoma [19], and hematologic malignancies [20].
In the present study, with a median follow-up time of
83.5 months, patients with high nuclear survivin expres-
sion had poorer overall survival than those with low
nuclear survivin expression (median duration, 120.8 vs.
192.5 months; hazard ratio, 8.567; 95% CI, 1.445- 50.783;
P = 0.018). Moreover, survivin expression, especially sub-
cellular nuclear localized expression, was a strong inde-
pendent negative predictor of overall survival. Little data
exist on the expression or clinical implications of survivin
in head and neck ACC. On the contrary, the clinical sig-
nificance of survivin expression in HNSCC has been
reported for oral [21], oropharyngeal [22], and laryngeal
carcinoma [23]. Our results are supported by several
reports. Lo Muzio et al. [21], in a series of 110 oral SCC
cases, found that patients with low survivin expression
had significantly better survival rates than patients with
medium and high survivin expression. Presuss et al. [22]
showed that nuclear survivin expression was associated
with a poor overall survival rate, with an estimated 3-year
overall survival probability of 17.3% vs. 87.4% for non-
nuclear expression of survivin (p < 0.001) in 73 patients
with surgically treated oropharyngeal SCC. Dong et al.
[23] examined 102 cases of laryngeal SCC, and found
that survivin expression was significantly associated with
shorter disease-free and overall survival (hazard ratio,
0.2696; 95% CI, 0.02666-0.85475; P 0.05).
I nc o n t r a s t ,F r e i e re ta l .[ 2 4 ]f o u n dt h a th i g hs u r v i v i n
expression was associated with increased 3-year, 5-year,
and 10-year overall survival in tumors from 296 patients
with advanced oral SCC who were treated with radio-
therapy (P = 0.005, P = 0.004 and P = 0.002, respec-
tively). The authors concluded that high survivin
expression might be useful for identifying patients with
oral SCC who could benefit from radiotherapy. These
inter-report differences may be associated with the his-
tological tumor types, different treatment modalities, the
various immunohistochemistry protocols and/or antibo-
dies used, or be due to variable criteria applied to anno-
tate a tumor as nuclear- or cytoplasmic-survivin
positive. In fact, Freier et al. did not analyze nuclear and
cytoplasmic staining to categorize immunostaining
independently.
Survivin exists in distinct nuclear and cytoplasmic
subcellular pools in human cancer cells [25]. However,
the clinical implications for subcellular localization of
survivin expression remains controversial. Among the
19 publications relevant to survivin localization in nuclei
or cytoplasm in various cancer tissues reviewed by Li
et al. [26], 9 showed that survivin expression in cancer
cell nuclei was an unfavorable prognostic marker,
whereas 5 proposed the opposing notion that nuclear
survivin expression represented a favorable prognostic
marker. Similarly, overall survivin expression, its discrete
intracellular localization, and its implication as a prog-
nostic marker were also analyzed in several HNSCC stu-
dies, albeit with opposing results [12,22,27]. In a series
of nine patients with laryngeal basaloid squamous cell
carcinoma, Marioni et al. [12] found that high nuclear
survivin expression is associated with disease recurrence
and poor prognosis (P = 0.02). Khan et al. [27] did not
find a significant correlation between the survivin
expression pattern and clinicopathological parameters in
patients with oral SCC. Lo Muzio et al. [21] in a series
of 110 cases of oral SCC, found a significant correlation
between the cytoplasmic survivin expression pattern and
poor clinical outcome. Recently, four alternatively spli-
cing transcripts have been identified in a single copy of
the survivin gene. In addition to wild-type survivin, four
survivin variants (survivin-2A,-2B,-3B and -ΔEx3) are
generated [28]. These transcripts may have different
subcellular localizations. All transport occurs through
the nuclear pore multiprotein complex. Recent convin-
cing experimental data suggest that survivin contains
Crm1-dependent nuclear export signals (NES) in the lin-
ker region between the BIR domain and the C-terminal
alpha helix. Consistent with this finding, the NES-defi-
cient survivin isoforms survivin-ΔEx3 and survivin-2A
do not localize predominantly in the cytoplasm, whereas
the NES-containing variants survivin-2B and survivin-3B
are cytoplasmic [29]. Nuclear survivin is also a subunit
of the chromosomal passenger complex, which ensures
the correct completion of cytokinesis and is composed
of the mitotic kinase aurora-B, borealin, and INCENP
[30]. However, their functions in carcinogenesis are lar-
gely unknown, and why survivin displays a predominant
nuclear localization in some tumors but not in others is
unclear. Functionally, one could consider that the
nuclear pool of survivin is involved in promoting cell
proliferation in most cases, whereas cytoplasmic survivin
may participate in controlling cell survival but not cell
proliferation. Nuclear survivin may help maintain the
integrity of the mitotic spindle in cancer cells [30], and
strong nuclear survivin staining may represent an
increased number of mitotic events, resulting in poor
survival [10]. In many immunohistochemical studies,
nuclear survivin expression is an unfavorable factor for
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[32], esophageal squamous cell carcinoma [11], colorec-
tal carcinoma [8], soft-tissue sarcoma [19], breast cancer
[9], laryngeal squamous cell carcinoma [12], hepatocel-
lular carcinoma [33], ovarian carcinoma [34], non-small
cell lung carcinoma [10], and glioblastoma [13]. In con-
trast, few studies have reported immunohistochemical
cytoplasmic survivin expression as an unfavorable factor
in patients with colorectal cancer [30], pancreatic cancer
[35], or oral squamous cell carcinoma [21]. Thus,
further investigations are required to clarify the prog-
nostic value of nuclear/cytoplasmic survivin expression.
In this study, nuclear and cytoplasmic survivin was
highly expressed in 62.2% and 83.8% of the ACC speci-
mens, respectively. Similarly, in HNSCC, despite the use
of variable cut-off values, previous studies have reported
that survivin is expressed in 12% to 72% of patients with
HNSCC [27,36]. The analysis of survivin and the clini-
copathological factors showed a significant association
between tissue expression of survivin and tumor size
but not lymph node involvement, which has also been
observed in previous studies on other cancers, including
laryngeal cancer [23]. The correlation between survivin
expression and tumor stage or the presence of lymph
node metastases in patients with primary HNSCC is still
a matter of debate. In Khan et al., there was no signifi-
cant association between survivin and tumor stage. Con-
sidering lymph node metastasis, Marioni et al. [36], in
an evaluation of 13 consecutive cases of oral and oro-
pharyngeal SCC with pN+ and 13 cases of pN0, demon-
strated that eight patients in the pN+ group were
survivin-positive (mean expression 34.7%), compared to
five in the pN0 group (12.3%), and this difference was
statistically significant (P = 0.017). In contrast, Lo
Muzio et al. [21], in an analysis of 110 oral SCC cases,
reported that there was no significant correlation
between survivin expression and the presence of lymph
node metastases.
We found that the association between survivin expres-
sion and bcl-2 was correlated statistically (nuclear expres-
sion, P = 0.031; cytoplasmic expression, P =0 . 0 7 8 ) .T h e
bcl-2 oncoprotein is a potent inhibitor of apoptosis and
is overexpressed in a wide variety of malignancies,
including salivary gland tumors [17]. One of antiapopto-
tic mechanisms by which bcl-2 may mediate cell cytopro-
tection independently of cytochrome c release is through
increased survivin expression [37]. However, we did not
find significant correlations between survivin and p53 or
ki-67 expression. Khan et al. [27], in a series of 29 oral
SCC cases, observed that about half of the p53-positive
oral SCC and premalignant tissues also showed signifi-
cant survivin positivity. Furthermore, Ki-67 was
e x p r e s s e da tar a t eo f1 0 . 8 % ,i nc o n t r a s tt ot h a to fs u r v i -
vin. This relatively low expression Ki-67 rate may explain
the indolent natural course of head and neck ACC [38].
Ki-67 values greater than 10% have been demonstrated
to be the most significant indicator of short-term clinical
course in ACC [39].
The present study has several limitations. First, it was a
relatively small number of patients. Second, we measured
expression using only immunohistochemical staining,
which has several weak points, including a semiquantita-
tive nature, tissue aging effects, the staining technique,
the enzyme antibody used, and single observer bias.
In conclusion, the present study demonstrated that
nuclear survivin expression has clinicopathological
implications in patients with head and neck ACC. We
expect that our data on the clinical implications of sur-
vivin will provide new insights into the management of
head and neck ACC. Survivin may be an ideal target for
therapy to improve the prognosis of patients with head
and neck ACC. Further investigation is necessary to
clarify and understand the roles of survivin in patients
with head and neck ACC.
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